Psychedelics – reasons for caution: Stacy Fischer, Brian Anderson, Theora Cimino
GeriPal
MARCH 9, 2023
FDA is considering approval, shifting away from Schedule I restrictions, paving the way for use in clinical practice. Potential use in palliative care , chronic pain , and for mood disorders is tantalizing. Early data on efficacy in patients with anxiety and demoralization are promising. Research is exploding.
91 
Let's personalize your content